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Chandelier cells (ChCs), typified by their unique
axonal morphology, are the most distinct interneu-
rons present in cortical circuits. Via their distinctive
axonal terminals, called cartridges, these cells selec-
tively target the axon initial segment of pyramidal
cells and control action potential initiation; however,
the mechanisms that govern the characteristic ChC
axonal structure have remained elusive. Here, by
employing an in utero electroporation-basedmethod
that enables genetic labeling and manipulation of
ChCs in vivo, we identify DOCK7, a member of the
DOCK180 family, as a molecule essential for ChC
cartridge and bouton development. Furthermore,
we present evidence that DOCK7 functions as a
cytoplasmic activator of the schizophrenia-associ-
ated ErbB4 receptor tyrosine kinase and that
DOCK7 modulates ErbB4 activity to control ChC
cartridge and bouton development. Thus, our find-
ings define DOCK7 and ErbB4 as key components
of a pathway that controls the morphological differ-
entiation of ChCs, with implications for the patho-
genesis of schizophrenia.
INTRODUCTION
Thematuration and function of cortical networks depend on intri-
cate interactions between glutamatergic pyramidal neurons
(PyNs) and GABAergic interneurons. PyNs are typically special-
ized to transmit information across cortical layers and regions,
and interneurons play important roles in controlling and shaping
the output of local PyNs. Therefore, interneurons are essential to
the function, complexity, and computational architecture of
neural circuits (Batista-Brito and Fishell, 2009; Huang et al.,
2007; Marı´n, 2012). Among the various interneuron subtypes,
chandelier cells (ChCs) in particular are believed to have power-254 Cell Reports 6, 254–263, January 30, 2014 ª2014 The Authorsful control over the output of PyNs, owing to their unique
morphology and type of connections they make (Howard et al.,
2005; Somogyi, 1977; Woodruff et al., 2010). Indeed, ChCs
possess a very distinctive axonal arbor with multiple arrays of
short vertical sets of cartridges, each harboring a string of synap-
tic boutons (Howard et al., 2005; Inda et al., 2009). This unique
architecture enables a single ChC to couple to a large population
of PyNs. Furthermore, ChCs selectively innervate the axon initial
segment (AIS) of PyNs (DeFelipe et al., 1985; Somogyi, 1977), the
most excitable part of a neuron where the action potential is
initiated (Ogawa and Rasband, 2008). Together, these charac-
teristics make ChCs ideally suited to exert powerful control
over the spiking of a large group of PyNs.
In concurrence with an important role for ChCs in controlling
cortical network activity, changes in ChC cartridges/boutons
and/or function have been reported in disease states such as
schizophrenia (DeFelipe, 1999; Lewis, 2012). For instance, a
decrease in ChC cartridge and/or bouton density in the pre-
frontal cortex of individuals with schizophrenia has been
described (Pierri et al., 1999;Woo et al., 1998). To date, however,
details on ChC cartridge/bouton development and synaptic
arborization remain scarce (Fish et al., 2013; Inan et al., 2013; Ta-
niguchi et al., 2013), and little is known about the molecular
mechanisms that govern the morphological differentiation and
functional maturation of ChCs (Fazzari et al., 2010). The main
obstacles have been a lack of unique biochemical ChC markers
and versatile methods to target and manipulate gene expression
in these cells.
In recent studies examining the expression patterns of
members of the DOCK180 family, an atypical class of Rac and/
or Cdc42 GTPase guanine nucleotide exchange factors (GEFs)
(Coˆte´ and Vuori, 2002; Meller et al., 2005; Miyamoto and Yamau-
chi, 2010), in GABAergic interneurons, we intriguingly observed
the presence of the DOCK7 family member, among other parval-
bumin (PV)-expressing interneurons, in ChCs of adolescent/
adult mouse brains. DOCK7 was previously shown to control
the polarization and genesis of newborn pyramidal neurons by
promoting Rac activity and antagonizing TACC3 (transforming
acidic coiled-coil-containing protein 3) function, respectively
Figure 1. Delivery of Gene Expression to ChCs by In Utero Electroporation
(A) Schematic drawing depicting the 60 angle of incline of electrode paddles with respect to the horizontal plane of the fetus’s brain used to direct DNA
transfection toward the ventral medial ganglionic eminence (vMGE).
(B) Representative image of ChC in layer II/III of somatosensory cortex from amouse electroporated at E12.5 with an EGFP-expressing plasmid and sacrificed at
P28. Scale bar, 20 mm.
(C) Example of cortical layer II/III ChC extending a single axonal branch into layer VI to innervate AISs of layer VI PyNs. Mouse embryos were electroporated at
E12.5 with an EGFP-expressing plasmid and sacrificed at P28. (C1) Entire view of layer II/III ChC innervating AISs of both layer II/III and layer VI PyNs. Insert on the
top, right is a lower magnification of ChC on the left showing intact cell. Scale bars, 20 mm (bottom) and 100 mm (top). (C2, C3) Detailed view of cartridges of ChC
depicted in (C1) innervating AISs of layer II/III (C2) and layer VI (C3) PyNs. Scale bar, 10 mm.
(D) Representative images of ChC cartridges contacting AIS of PyNs. Scale bar, 10 mm.
AISs of PyNs (in B, C, and D) are visualized by immunostaining with an antibody to phospho-IkappaB (pIkB).(Watabe-Uchida et al., 2006; Yang et al., 2012). Here, by imple-
menting an in utero electroporation-based method that enables
genetic labeling and manipulation of ChCs at single-cell resolu-
tion, we demonstrate a key role for DOCK7 in ChC cartridge/
bouton development. Furthermore, we show that DOCK7 inter-
acts with and positively modulates the activity of the schizo-
phrenia-associated ErbB4 receptor tyrosine kinase (RTK), a
member of the ErbB family whose expression is largely confined
to PV-expressing ChCs and basket cells in the cerebral cortex
(Del Pino et al., 2013; Fazzari et al., 2010). Most importantly,
we present evidence that DOCK7 controls ChC cartridge/bouton
development by modulating the activity of ErbB4. Thus, our data
unveil a critical role for DOCK7 as a cytoplasmic modulator of
ErbB4 activity in the regulation of ChC cartridge/bouton
development.
RESULTS
Delivery of Gene Expression to ChCs by Directional In
Utero Electroporation
Based on recent evidence indicating that progenitors in the
ventral medial ganglionic eminence (vMGE) provide a source of
ChCs (Inan et al., 2012; Taniguchi et al., 2013), we reasoned itCshould be possible to target gene expression in nascent ChCs
by means of in utero electroporation directed toward the
vMGE. To this end, we introduced an enhanced green fluores-
cent protein (EGFP) encoding plasmid into the lateral ventricle
of embryonic day 12.5 (E12.5) to E13.5 mouse embryos and
directed the current and DNA transfection toward the vMGE by
placing electrodes at about 60 from the brain’s horizontal plane
(Figure 1A). Animals that developed from electroporated em-
bryos were sacrificed at postnatal day 28 (P28), when ChCs
are fully differentiated, and brain slices analyzed. Strikingly,
using this approach we were able to reproducibly transfect
and fluorescently label, among some other interneurons, ChCs
at single-cell resolution. EGFP-transfected ChCs were detected
in the neocortex, archicortex, and amygdala (Figures 1B and S1),
consistent with previous immunohistochemical studies (DeFe-
lipe et al., 1985; Inda et al., 2009; McDonald, 1982; Sik et al.,
1993; Somogyi et al., 1982).
Within the neocortex, GFP-labeled ChCs were detected in
layer II/III, layer V, and layer VI (Figures S1D–S1F), though layer
II/III ChCs were most frequently targeted. Indeed, we found
that all EGFP-labeled ChCs resided in layers II/III when electro-
porations were performed at E12.5, and, remarkably, only
when electroporations were performed at E13.5, we found aboutell Reports 6, 254–263, January 30, 2014 ª2014 The Authors 255
10% of the labeled ChCs in layers V and VI. Intriguingly, besides
innervating AISs of PyNs within the same layer, we noted that
some layer II/III ChCs also extended a single axonal branch
across different layers reaching as far as layer VI to innervate
AISs of layer VI PyNs (Figure 1C). This is of particular interest,
as this property could endow ChCs with the ability to synchro-
nize neuronal activity across cortical layers. We further analyzed
inmore detail the cartridges of layer II/III ChCs.We quantified the
average length of the cartridges to be 22.2 ± 6.4 mm (mean ±
SEM; n = 64 cartridges from nine ChCs), each containing on
average 7.1 ± 2.0 boutons (mean ± SEM; n = 64 cartridges
from nine ChCs). The average distance between the bouton
located proximal to the cell body on the AIS and the cell body
of target PyNs was 10.9 ± 4.4 mm (mean ±SEM; n = 64 cartridges
from nine ChCs). Given that overall the length of the AISs of layer
II/III mouse cortical neurons is 30 mm, these findings imply that
ChC cartridges preferentially innervate the distal part of the AIS.
Noteworthy, while cartridges were generally reported to climb
upward along the AIS in a vertical position (Howard et al.,
2005; Somogyi et al., 1982), we found that they not only can
climb upward, but also descend down the AIS (Figures 1D1–
1D3), and form contacts with the AIS, despite the AIS not being
vertical to the pia (Figure 1D4). Moreover, the cartridges were
often branched (Figure 1D5), and in rare cases we noted that
more than one cartridge (two to three cartridges) from the
same GFP-labeled ChC innervated one AIS (Figure 1D6).
Together, these data demonstrate that vMGE-directed in utero
electroporation presents a versatile approach to deliver gene
expression in ChCs and is well suited for examining ChC
morphology at single-cell resolution.
DOCK7 Is Required for ChC Cartridge/Bouton
Development
We next tackled the identification of molecular mechanisms
that govern ChC cartridge/bouton development. As aforemen-
tioned, in studies examining the expression of DOCK180 family
members in GABAergic interneurons, we observed the presence
of DOCK7, among other PV-expressing interneurons (i.e., basket
cells), in ChCs of adolescent/adult mouse brains (Figure S2A;
data not shown). This finding prompted us to explore a potential
role for DOCK7 in the morphological differentiation of ChCs. To
this end, we combined the above-described in utero electropo-
ration approach with RNA interference (RNAi) to knock down
endogenous DOCK7 protein levels. For RNAi, we used previ-
ously described vectors that express a short hairpin RNA
(shRNA) targeting the DOCK7 protein coding sequence
(Dock7#1) or the 30 UTR (Dock7#2) of mouse DOCK7 mRNA or
a control scrambled (scr#1) shRNA (Watabe-Uchida et al.,
2006; Yang et al., 2012).
Akin to ChCs expressing EGFP alone, ChCs coexpressing
scr#1, Dock7#1, or Dock7#2 shRNA all resided in neocortical
layers II/III, when embryos were electroporated at E12.5. Inter-
estingly, althoughDOCK7 knockdown did not prevent the forma-
tion of ChC dendrites and axons, the axonal cartridges of both
Dock7#1 and Dock7#2 shRNA-expressing ChCs were disorga-
nized in comparison to those of scr#1 shRNA-expressing
ChCs (Figures 2A and 2B; data not shown). This was particularly
evident when the electroporated neocortices were coimmunos-256 Cell Reports 6, 254–263, January 30, 2014 ª2014 The Authorstained with a pIkB antibody, which labels the AIS of neighboring
PyNs (Figures 2D and 2E). Also, we found that both Dock7#1 and
Dock7#2 shRNA significantly decreased the density and size
of boutons compared to scr#1 shRNA (Figures 2A, 2B, 2G, and
2H), whereas no significant difference in cartridge length was
observed (Figure S2B). Rescue experiments using DOCK7
cDNA that lacks the 30 UTR and is therefore resistant to
Dock#2 shRNA-mediated RNA interference demonstrated that
the effects of DOCK7 RNAi were specific (Figures 2C, 2F, 2G,
and 2H). To further establish the requirement of DOCK7 for
ChC bouton development, we examined whether knockdown
of DOCK7 in ChCs at later developmental stages (after P7–P8)
also leads to a decrease in bouton size and density. To this
end, we engineered a Cre-dependent inducible RNAi expression
vector targeted against DOCK7 (Figures S3A and S3B). This
vector was coelectroporated with a vector expressing a tamox-
ifen-inducible form of Cre recombinase in E12.5 embryos.
Tamoxifen was then delivered to pups at P7–P8, and animals
were sacrificed at P28 and ChCs analyzed (Figure S3C). We
found that also in this case DOCK7 knockdown causes a
decrease in bouton size and density, while no apparent axonal
phenotype is observed (Figures S3C–S3G), corroborating that
DOCK7 is required for proper ChC bouton development. Of
note, knockdown of DOCK7 in PV-expressing basket cells (at
E12.5, as in Figure 2) did not affect the bouton density of these
cells (Figure S2E).
We then examined the effects of DOCK7 overexpression
on ChC morphology and essentially observed the opposite
phenotypes than those seen for DOCK7 RNAi. An organized
network of ChC cartridges was formed, with cartridges inner-
vating AISs of their postsynaptic target cells (Figures 2I–2L).
Furthermore, both the density and size of boutons of Flag-
DOCK7-expressing ChCs were increased compared to con-
trol-vector-expressing cells (Figures 2I, 2J, 2M, and 2N),
whereas cartridge length and number was not affected (Figures
S2C and S2D). Together, these data unveil a critical role for
DOCK7 in ChC cartridge/bouton development.
DOCK7 Is a Cytoplasmic Activator of the ErbB4
Receptor
Besides DOCK7, the only other protein hitherto implicated in
ChC bouton formation is the ErbB4 RTK. In particular, recent
studies demonstrated a decrease in ChC bouton number in
ErbB4 mutant mice, in which ErbB4 was conditionally deleted
in a subset of interneurons (Del Pino et al., 2013; Fazzari et al.,
2010). Interestingly, DOCK7 had previously been shown to
interact with the ErbB2 family member, playing a role in Schwann
cell myelination (Yamauchi et al., 2008). ErbB2, however, in
contrast to ErbB4, reportedly is not expressed in PV-expressing
basket and ChCs in the cerebral cortex (Birchmeier, 2009;
Fazzari et al., 2010). Also, we were unable to detect ErbB2
expression in ChCs (data not shown). Hence, we decided to
examine whether DOCK7 also interacts with ErbB4, and found
that this is indeed the case. Coimmunoprecipitation experiments
using extracts prepared from transiently transfected human
embryonic kidney 293 cells (HEK293) cells or mouse Neuro 2A
cells demonstrated that ErbB4 specifically coimmunoprecipi-
tated with DOCK7 and, vice versa, that DOCK7 specifically
Figure 2. Effects of Altered DOCK7 Expression on ChC Cartridge/Bouton Development
(A–H) DOCK7 knockdown impairs ChC cartridge/bouton development.
(A–C) Representative images of ChCs in layer II/III of somatosensory cortex from mice coelectroporated at E12.5 with plasmids expressing EGFP and scr#1
shRNA, Dock7#2 shRNA, or Dock7#2 RNA + Flag-DOCK7 (DOCK7) and sacrificed at P28. Enlarged view of ChC cartridges with boutons is depicted on bottom.
Scale bars, 20 mm (top) and 5 mm (bottom).
(D–F) Representative images illustrating innervation of AISs by cartridges of ChCs transfectedwith EGFP-expressing plasmid and one of the indicated constructs.
The AIS is visualized by immunostaining with an antibody to pIkB. Scale bar, 10 mm.
(G and H) Quantification of bouton density (G) and size (H). Data are mean ± SEM; 7–11 ChCs from three animals were analyzed for each condition, and for each
cell 7–15 cartridges (G) and 52–149 boutons (H) were analyzed. ***p < 0.001; ns (not significant) indicates pR 0.05, in comparison to scr#1; one-way ANOVA, post
hoc Tukey-Kramer test.
(I and N) Ectopic DOCK7 expression promotes ChC cartridge/bouton development.
(I and J) Representative images of ChCs in layer II/III of somatosensory cortex from mice coelectroporated at E12.5 with plasmids expressing EGFP and empty
control vector (vector) or Flag-DOCK7 (DOCK7) and sacrificed at P28. Enlarged view of ChC cartridges with boutons is depicted on the bottom. Scale bars, 20 mm
(top) and 5 mm (bottom).
(K and L) Representative images illustrating innervation of AISs by cartridges of ChCs transfected with EGFP-expressing plasmid and one of the indicated
constructs. Scale bar, 10 mm.
(M and N) Quantification of bouton density (M) and size (N). Data are mean ± SEM; 11 ChCs from three animals were analyzed for each condition, and for each cell
7–17 cartridges (M) and 54–155 boutons (N) were analyzed. ***p < 0.001; Student’s t test.
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Figure 3. DOCK7 Interacts with and Enhances Activation of ErbB4
(A) Schematic diagram of DOCK7 and ErbB4 domain structure. Dark brown box in ErbB4 represents hydrophobic transmembrane domain.
(B) DOCK7-ErbB4 interaction in human HEK293 cells. Extracts from HEK293 cells transiently expressing wild-type (WT), kinase-dead (K751M; KD), C-terminal
deletion mutant (DC), or cytoplasmic domain (C) of ErbB4-HA alone or in combination with Flag-DOCK7 (F-DOCK7) or Flag-DOCK7DDHR2 (F-DDHR2) were
immunoprecipitated (IP) with an antibody (Ab) to Flag and analyzed by western blotting with Abs to Flag and HA. WCE, whole cell extract.
(C) DOCK7-ErbB4 interaction in mouse Neuro 2A cells. Extracts from Neuro 2A cells transiently expressing ErbB4 WT alone or in combination with F-DOCK7 or
F-DDHR2 were immunoprecipitated with an Ab to ErbB4 and analyzed by western blotting with Abs to ErbB4 and Flag.
(D) Ectopic expression of DOCK7 or DOCK7DDHR2 increases tyrosine phosphorylation of ErbB4. Extracts from Neuro 2A cells transiently expressing ErbB4 WT
alone or in combination with F-DOCK7 or F-DDHR2 were immunoprecipitated with an Ab to ErbB4 and analyzed by western blotting with Abs to ErbB4,
phosphotyrosine (PY20), and Flag.
(E) Ectopic DOCK7 expression enhances autophosphorylation of WT, but not kinase-dead, ErbB4 and does so independently of its DHR2 domain. Extracts from
Neuro 2A cells transiently expressing WT or KD ErbB4 alone or in combination with F-DOCK7 (left) or ErbB4 WT alone or in combination with F-DOCK7 or
F-DDHR2 (right) were subjected to western blot analysis using Abs to phospho(p)-ErbB4 (Tyr1284), ErbB4, DOCK7, or Flag and to g-tubulin as a loading control.
(F) Knockdown of DOCK7 decreases autophosphorylation of ectopically expressed ErbB4 in Neuro 2A cells. Extracts from Neuro 2A cells transiently expressing
ErbB4 WT together with scr#1, Dock7#1, or Dock7#2 shRNA were subjected to western blot analysis with the indicated Abs.
(legend continued on next page)
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coimmunoprecipitated with ErbB4 (Figures 3A–3C). Interest-
ingly, we found that the DHR2 domain of DOCK7, which is
conserved among all DOCK180 family members and catalyzes
the exchange of GDP for GTP on Rac and/or Cdc42 (Watabe-
Uchida et al., 2006; Yamauchi et al., 2008), is dispensable for
its association with ErbB4 (Figure 3A–3C). DOCK7 still interacted
with a kinase-dead ErbB4 mutant (ErbB4-K751M; KD), but not
a C-terminally truncated ErbB4 mutant (ErbB4DC) lacking most
of the intracellular domain of ErbB4 (Figure 3B), indicating
that DOCK7 binding requires the C-terminal cytoplasmic domain
of ErbB4, but not its kinase activity. In accordance, DOCK7
associated with a fragment encoding just the cytoplasmic (C)
domain of ErbB4 (Figure 3B).
While initially we envisioned DOCK7 to be primarily involved
in mediating ErbB4 signaling, we surprisingly found that
DOCK7 plays a prominent role in the activation of ErbB4. The
first hint for this came from our observation that when DOCK7
or DOCK7DDHR2 was coexpressed with ErbB4 in Neuro 2A
cells, tyrosine phosphorylation of immunoprecipitated ErbB4
was consistently increased compared to the empty control
vector condition (Figure 3D). Notably, ErbB4, like all ErbB family
members is subject to ligand-independent tyrosine phosphory-
lation when ectopically expressed (Nagy et al., 2010). To extend
the above finding, we examined the effect of ectopic DOCK7
expression on ErbB4 autophosphorylation in Neuro 2A cells
transiently expressing ErbB4 using a phospho-specific antibody
that recognizes ErbB4 autophosphorylation at Tyr-1284. DOCK7
overexpression significantly increased the phosphorylation
of wild-type, but not kinase-dead, ErbB4 (Figure 3E). We
observed a similar increase in ErbB4 phosphorylation when
DOCK7DDHR2 was ectopically expressed, indicating that
DOCK7-induced ErbB4 activation does not require its GEF activ-
ity (Figure 3E, right panel).
We then examined whether conversely knockdown of DOCK7
diminishes ErbB4 activation by coexpressing the above-
described Dock7 shRNAs with ErbB4 into Neuro 2A cells. Both
Dock7#1 and Dock7#2 shRNA, but not scr#1 shRNA, signifi-
cantly reduced ErbB4 autophosphorylation (Figure 3F). We
further investigated the impact of DOCK7 knockdown on the
activation of endogenously expressed ErbB4. Since we were
unable to detect expression of endogenous ErbB4 in Neuro 2A
cells, we resorted to a culture of primary subcortical neurons,
in which ErbB4 expression was readily detected. These neurons
were infected with a lentivirus expressing scr#1 or Dock7#2
shRNA, and the infected neurons as well as uninfected neurons
(no) were either left unstimulated or stimulated with the ErbB4
ligand neuregulin-1 (NRG1) and analyzed for ErbB4 autophos-
phorylation. As expected, NRG1 treatment elicited a significant
increase in ErbB4 phosphorylation in uninfected cells and in cells(G) Knockdown of DOCK7 decreases autophosphorylation of endogenously expre
left uninfected (no) or were infected with lentivirus expressing scr#1 or Dock7#2
5 min. Cell extracts were prepared and subjected to western blot analysis with in
(H) DOCK7 enhances ErbB4 phosphorylation in a cell-free system. Recombina
combinant Flag/His6-DOCK7 protein (generated in insect cells) in the absence (
addition of Laemmli buffer, and proteins were subjected to western blot analysis
The numbers below (E)–(H) represent changes (n-fold) in signal intensities of PY20
control condition. Numbers are the average of three to four independent experim
Cexpressing scr#1 shRNA (Figure 3G). This increase was signifi-
cantly reduced in cells expressing Dock7#2 shRNA (Figure 3G).
Thus, these data corroborate the involvement of DOCK7 in the
activation of ErbB4.
Finally, we determined whether DOCK7 could directly activate
ErbB4. To this end, we performed an in vitro phosphorylation
assay using commercially available purified ErbB4 protein and
recombinant full-length DOCK7 protein produced in Sf9 insect
cells or obtained from transiently transfected HEK293T cells.
When DOCK7 was added at increasing amounts to the reaction
buffer containing ErbB4, a dose-dependent increase in ErbB4
tyrosine phosphorylation was observed (Figures 3H and S4A),
demonstrating that DOCK7 can indeed directly activate ErbB4.
Together, these data indicate that DOCK7 acts as a cytoplasmic
activator of ErbB4.
DOCK7 Modulates ErbB4 Activity to Regulate ChC
Cartridge/Bouton Development
Next, we investigated the role and importance of DOCK7-medi-
ated ErbB4 activation in ChC cartridge/bouton development. To
approach this, we first examined the consequences of enhanced
and reduced ErbB4 activity/expression onChC cartridge/bouton
development in our experimental system. For the former, we
used a previously described ErbB4mutant, ErbB4-E836K, which
has been shown to display enhanced kinase activity (Prickett
et al., 2009). For the latter, we used a previously described
ErbB4 shRNA (ErbB4#2) (Li et al., 2007), which we confirmed
to be effective in reducing ErbB4 protein levels (Figure S4C).
E12.5 embryos were coelectroporated with vectors express-
ing EGFP and ErbB4-E836K, ErbB4#2 shRNA, or corresponding
control vectors, and brain slices were prepared and analyzed
at P28 as described above. We observed that in ErbB4-E836K
expressing cells the cartridges formed awell-organized network,
while in ErbB4#2 shRNA-expressing cells they appeared less
organized (Figures 4A, 4B, 4G, and 4H). Moreover, the density
and size of ChC boutons were increased and decreased,
respectively, in ErbB4-E836K and ErbB4#2 shRNA-transfected
ChCs compared to those in the control groups (Figures 4E, 4F,
4K, and 4L). Thus, the phenotypes produced by ErbB4 gain-
and loss-of-function variants in ChCs largely resemble those of
DOCK7 gain- and loss-of-function, consistent with the idea
that DOCK7 could control ChC cartridge/bouton development
via ErbB4-mediated signaling.
To further establish this, we examined whether coexpression
of ErbB4-E836K with Dock7#2 shRNA could overcome the
ChC cartridge/bouton phenotypes evoked by DOCK7 RNAi
and, conversely, whether coexpression of ErbB4#2 shRNA
with Flag-DOCK7 could counteract the phenotypes elicited by
ectopic DOCK7 expression. We found that ErbB4-E836K wasssed ErbB4 in cultured subcortical neurons. Cultured subcortical neuronswere
shRNA and left unstimulated () or stimulated (+) with neuregulin-1 (NRG1) for
dicated Abs.
nt ErbB4-Myc protein (20 ng) was incubated with increasing amounts of re-
) or presence (+) of ATP for 30 min at 30C. The reaction was terminated by
with the indicated Abs.
or pErbB4 normalized to those of total ErbB4 and then to the value of 1.0 for the
ents.
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Figure 4. DOCK7 Regulates ChC Cartridge/Bouton Development by Modulating ErbB4 Activity
(A–D) Representative images of ChCs in layer II/III of somatosensory cortex from mice coelectroporated at E12.5 with plasmids expressing EGFP and empty
control vector, ErbB4-E836K, Dock7#2 shRNA + vector, or Dock7#2 shRNA + ErbB4-E836K and sacrificed at P28. Enlarged view of ChC cartridges with boutons
is depicted on the right. Scale bars, 20 mm (left) and 5 mm (right).
(E and F) Quantification of bouton density (E) and size (F). Data are mean ± SEM; 10–11 ChCs from three animals were analyzed for each condition, and for each
cell 7–20 cartridges (E) and 90–162 boutons (F) were analyzed. ***p < 0.001, in comparison to vector; one-way ANOVA, post hoc Tukey-Kramer test.
(G–J) Representative images of ChCs in layer II/III of somatosensory cortex from mice coelectroporated at E12.5 with plasmids expressing EGFP and scr#2
shRNA, ErbB4#2 shRNA, Flag-DOCK7 + scr#2 shRNA, or Flag-DOCK7 + ErbB4#2 shRNA and sacrificed at P28. Enlarged view of ChC cartridges with boutons is
depicted on the right. Scale bars, 20 mm (left) and 5 mm (right).
(K and L) Quantification of bouton density (K) and size (L). Data aremean ±SEM; 9–17 ChCs from three animals were analyzed for each condition, and for each cell
7–17 cartridges (K) and 91–158 boutons (L) were analyzed. ***p < 0.001, in comparison to scr#2; one-way ANOVA, post hoc Tukey-Kramer test.
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able to overcome the decrease in bouton size and density, as
well as cartridge disorganization, produced by DOCK7 RNAi
(Figures 4C–4F), while ErbB4#2 shRNA prevented the increase
in bouton size and density triggered by ectopic DOCK7 expres-
sion (Figures 4I–4L). Together with our biochemical data, these
findings support a model in which DOCK7 modulates ErbB4 ac-
tivity to regulate ChC cartridge/bouton development.
DISCUSSION
In this study, we describe an in utero electroporation-based
method to fluorescently label single ChCs and manipulate
gene expression in these cells. This approach enabled us to
monitor ChCs at high cellular resolution, providing insights into
ChC cartridge innervation of the AIS, and, significantly, leading
to the identification of DOCK7 as a key regulator of ChC
cartridge/bouton development. We further found that DOCK7,
independent of its GEF activity, acts as a cytoplasmic activator
of the RTK ErbB4, and importantly that DOCK7 promotes ChC
cartridge/bouton development by enhancing ErbB4 activation.
ChCs so far have been identified only in mammals and found
to be located in the neocortex, archicortex (i.e., hippocampus,
piriform cortex), and amygdala (DeFelipe et al., 1985; Inda
et al., 2009; McDonald, 1982; Sik et al., 1993; Somogyi et al.,
1982). The developmental origin of ChCs in these three brain
regions has been long sought after. Recent studies unveiled
the vMGE and the ventral germinal zone (VGZ), likely a remnant
or extension of the medial ganglionic eminence (MGE), as a
source of neocortical ChCs, with the production of ChCs being
noted as early as E13.5, increasing at E15, and reaching a
peak at about E16 when the MGE has disappeared morpholog-
ically and the VGZ has emerged (Inan et al., 2012; Taniguchi
et al., 2013). As to the origin of ChCs in the hippocampus and
amygdala, this remains largely elusive. Intriguingly, by applying
vMGE-directed in utero electroporation to developing mouse
embryos (stages E12.5–E13.5), we were able to sparsely, but
reproducibly, target gene expression in ChCs in all of the above
three brain areas. Notably, we chose E12.5–E13.5, because at
this stage the proliferative zone of the vMGE is directly adjacent
to the lateral ventricle and hence readily accessible for gene
transfer from that site. We infer from these data that a common
pool or potentially distinct pools of ChC progenitors for the
hippocampus, amygdala, and neocortex exist(s) from midgesta-
tion in the vMGE and that these progenitors then likely become
competent in a temporally regulated manner to give rise to
ChCs in the different brain regions. Future studies will, however,
be required to further determine that this is the case.
Taking advantage of the versatility of electroporation to alter
gene expression and the fact that ChCs are sparsely labeled
by vMGE-directed in utero electroporation, we were able to
demonstrate that normal DOCK7 expression within individual
ChCs is essential for the proper development of ChC cartridges
and boutons. Indeed, knockdown of DOCK7 in ChCs in cortical
regions resulted in a disorganized network of ChC cartridges and
a reduction in the number and size of boutons, while ectopic
expression of DOCK7 brought about the opposite phenotypes.
Our findings further indicate that other DOCK180 family
members do not compensate for this function of DOCK7, asCknockdown of DOCK7 alone is sufficient to cause defects in
ChC cartridge/bouton development. It is noteworthy that previ-
ous studies had implicated DOCK7 function in Schwann cell
myelination (Yamauchi et al., 2008) and the polarization (Wa-
tabe-Uchida et al., 2006) and genesis of newborn pyramidal
neurons (Yang et al., 2012). While DOCK7 was shown to regulate
these processes via its interaction with Rac1/Cdc42 GTPases
(Watabe-Uchida et al., 2006; Yamauchi et al., 2008) or
the centrosome- and microtubule-associated protein TACC3
(Yang et al., 2012), we found here that DOCK7 controls ChC
cartridge/bouton development via its interaction with ErbB4
(see further below). Combined, these findings imply that
DOCK7 exerts specific yet distinct roles in different cell types
and does so by engaging in different protein-protein interactions.
In this regard, multiple and nonredundant functions, often cell-
type specific, have previously been demonstrated for several
DOCK180 family members (Chen et al., 2009; Fukui et al.,
2001; Laurin et al., 2008; Miyamoto and Yamauchi, 2010; Ran-
dall et al., 2011; Vives et al., 2011).
The first clue toward themechanismbywhichDOCK7 controls
ChC cartridge/bouton development came from our findings that
DOCK7 interacts with the cytoplasmic domain of ErbB4 and,
importantly, that it functions as a cytoplasmic activator of
ErbB4. Indeed, we found that DOCK7 knockdown decreases
and ectopic DOCK7 expression enhances ErbB4 activation.
This function of DOCK7 does not require its catalytic DHR2
domain, indicating that DOCK7 enhances ErbB4 activation
independently of its GEF activity. Noteworthy, so far only two
other cytoplasmic activators of RTKs have been described.
One is the adaptor protein Dok7, which activates the muscle-
specific RTK MuSK and controls neuromuscular junction forma-
tion (Bergamin et al., 2010; Yamanashi et al., 2012). The other is
the ARF-GEF ARNO, which enhances the activation of the EGFR
and promotes the proliferation of EGFR-dependent tumor cells
(Bill et al., 2010).
The importance of ErbB4 activation for DOCK7 function in
ChC differentiation is supported by several of our findings. For
starters, the phenotypes elicited by ErbB4 gain- and loss-of-
function variants in ChCs largely resemble those of DOCK7
gain and loss of function. More importantly, we found that an
ErbB4 mutant with enhanced kinase activity was able to over-
come the phenotypes associated with DOCK7 knockdown.
Conversely, silencing of ErbB4 prevented the phenotypes
elicited by DOCK7 overexpression. Together with our bio-
chemical data, these findings support a model in which
DOCK7 controls ChC cartridge/bouton development by modu-
lating ErbB4 activity and thereby its downstream signaling.
What signaling pathway(s) mediate the effects of DOCK7/
ErbB4 on ChC cartridge/bouton development remains an open
question to be addressed in the future. Of interest is our finding
that DOCK7 itself becomes tyrosine phosphorylated by ErbB4
(see Figure S4B), raising the possibility that a positive feedback
loop exists, with DOCK7 enhancing ErbB4 activation and the
latter in turn priming DOCK7 function; e.g., by facilitating
DOCK7 recruitment to the membrane and/or eliciting a confor-
mational change in DOCK7.
In summary, this study demonstrates the successful use of
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molecular mechanisms that govern the morphological differ-
entiation of ChCs. We uncovered a critical role for DOCK7 as
a cytoplasmic activator of ErbB4 in the regulation of ChC
cartridge/bouton development. A key feature of defective
DOCK7/ErbB4 signaling is a decrease in the number and size
of ChC boutons, which interestingly is one of the most salient
features of individuals with schizophrenia (Pierri et al., 1999;
Woo et al., 1998). We envisage that such morphological
changes are likely to impact the physiological properties of
ChCs and, consequently, alter cortical network activity (Szaba-
dics et al., 2006; Woodruff et al., 2011), which is thought to
contribute to the cognitive abnormalities characteristic of
schizophrenia (Lewis, 2012).EXPERIMENTAL PROCEDURES
DNA and RNAi constructs, cell culture, and methods for transfection and viral
infection are included in the Supplemental Experimental Procedures.
In Utero Electroporation
Timed-pregnant CD1 mice (Charles River) at 12.5 or 13.5 days of gestation
were anesthetized, the uterine horns were exposed, and 1 to 2 ml of DNA
solution (final concentration 1 mg/ml) was injected manually into the lateral
ventricle of the embryos using a beveled glass micropipette. Custom-made
tweezer electrodes were placed at about 60 from the brain’s horizontal plane
so as to direct the current toward the vMGE. Electric pulses (35 V; 50 ms) were
passed five times at 1 s intervals using an electroporator (BTX, ECM830). After
electroporation, the uterus was placed back in the abdominal cavity and the
wound surgically sutured. Embryos were allowed to develop normally, and
animals were sacrificed at P28, when ChCs are fully differentiated. ChCs
were sparsely labeled using this method (approximately three to six cells in
somatosensory cortex). Of note, the number of other interneurons targeted
in the somatosensory cortex was more variable, ranging from 20 to 80. All an-
imal care protocols were approved by CSHL.
Confocal Image Acquisition and Analysis
Images were acquired using a confocal microscope (Zeiss) with a 633 oil-
immersion objective. Sequential acquisition settings were applied at the
resolution of 2,048 3 2,048. Each image was a z series of 30–40 images at
1 mm depth interval. The resultant z stack was ‘‘flattened’’ into a single image
using maximal projection. ChC cartridges were randomly chosen within a
150-mm-diameter circle centered on the cell body, and varicosities (boutons)
were labeled with NeuroLucida software. Bouton density was determined by
measuring cartridge length and counting the number of varicosities on each
cartridge and represented as the number of varicosities divided by cartridge
length. Bouton size was determined by measuring the diameter of a bouton
parallel to the ChC axon using Zeiss LSM software. Preparation of brain slices
and immunohistochemistry staining methods are described in the Supple-
mental Experimental Procedures.
Biochemical Analysis
Western blotting, coimmunoprecipitations, protein purification, and in vitro
ErbB4 phosphorylation assay were performed largely as described elsewhere
(Bill et al., 2010; Yamauchi et al., 2008; Yang et al., 2012). See the Supple-
mental Experimental Procedures for details.
Statistical Analysis
Data are presented as mean ± SEM from at least three independent experi-
ments. Direct comparisons were made using Student’s t test and multiple
group comparisons using one-way analysis of variance (ANOVA) with a post
hoc Tukey-Kramer multiple comparison test. Statistical significance was
defined as p < 0.01 or 0.001 (indicated as ** or ***, respectively). p values R
0.05 were considered not significant.262 Cell Reports 6, 254–263, January 30, 2014 ª2014 The AuthorsSUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2013.12.034.
ACKNOWLEDGMENTS
We thank Z.J. Huang, members of the L.V.A. lab, J. Skowronski, and E-.E.
Govek for discussions and/or critical reading of the manuscript. We also thank
Y-.T. Yang and S. Mitra Uyaniker for technical assistance. This work was sup-
ported by National Institutes of Health (NIH) grants R01 MH082808 and R01
NS082266 to L.V.A. C.-L.W. is supported by NIH grant T32 CA148056-1.
Received: August 15, 2013
Revised: November 1, 2013
Accepted: December 20, 2013
Published: January 16, 2014
REFERENCES
Batista-Brito, R., and Fishell, G. (2009). The developmental integration of
cortical interneurons into a functional network. Curr. Top. Dev. Biol. 87,
81–118.
Bergamin, E., Hallock, P.T., Burden, S.J., and Hubbard, S.R. (2010). The cyto-
plasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via
dimerization. Mol. Cell 39, 100–109.
Bill, A., Schmitz, A., Albertoni, B., Song, J.N., Heukamp, L.C., Walrafen, D.,
Thorwirth, F., Verveer, P.J., Zimmer, S., Meffert, L., et al. (2010). Cytohesins
are cytoplasmic ErbB receptor activators. Cell 143, 201–211.
Birchmeier, C. (2009). ErbB receptors and the development of the nervous
system. Exp. Cell Res. 315, 611–618.
Chen, Q., Peto, C.A., Shelton, G.D., Mizisin, A., Sawchenko, P.E., and Schu-
bert, D. (2009). Loss of modifier of cell adhesion reveals a pathway leading
to axonal degeneration. J. Neurosci. 29, 118–130.
Coˆte´, J.F., and Vuori, K. (2002). Identification of an evolutionarily conserved
superfamily of DOCK180-related proteins with guanine nucleotide exchange
activity. J. Cell Sci. 115, 4901–4913.
DeFelipe, J. (1999). Chandelier cells and epilepsy. Brain 122, 1807–1822.
DeFelipe, J., Hendry, S.H., Jones, E.G., and Schmechel, D. (1985). Variability
in the terminations of GABAergic chandelier cell axons on initial segments of
pyramidal cell axons in the monkey sensory-motor cortex. J. Comp. Neurol.
231, 364–384.
Del Pino, I., Garcı´a-Frigola, C., Dehorter, N., Brotons-Mas, J.R., Alvarez-
Salvado, E., Martı´nez de Lagra´n, M., Ciceri, G., Gabaldo´n, M.V., Moratal, D.,
Dierssen, M., et al. (2013). Erbb4 deletion from fast-spiking interneurons
causes schizophrenia-like phenotypes. Neuron 79, 1152–1168.
Fazzari, P., Paternain, A.V., Valiente, M., Pla, R., Luja´n, R., Lloyd, K., Lerma, J.,
Marı´n, O., and Rico, B. (2010). Control of cortical GABA circuitry development
by Nrg1 and ErbB4 signalling. Nature 464, 1376–1380.
Fish, K.N., Hoftman, G.D., Sheikh, W., Kitchens, M., and Lewis, D.A. (2013).
Parvalbumin-containing chandelier and basket cell boutons have distinctive
modes of maturation in monkey prefrontal cortex. J. Neurosci. 33, 8352–8358.
Fukui, Y., Hashimoto, O., Sanui, T., Oono, T., Koga, H., Abe, M., Inayoshi, A.,
Noda, M., Oike, M., Shirai, T., and Sasazuki, T. (2001). Haematopoietic cell-
specific CDM family protein DOCK2 is essential for lymphocyte migration.
Nature 412, 826–831.
Howard, A., Tamas, G., and Soltesz, I. (2005). Lighting the chandelier: new
vistas for axo-axonic cells. Trends Neurosci. 28, 310–316.
Huang, Z.J., Di Cristo, G., and Ango, F. (2007). Development of GABA innerva-
tion in the cerebral and cerebellar cortices. Nat. Rev. Neurosci. 8, 673–686.
Inan, M., Welagen, J., and Anderson, S.A. (2012). Spatial and temporal bias in
the mitotic origins of somatostatin- and parvalbumin-expressing interneuron
subgroups and the chandelier subtype in the medial ganglionic eminence.
Cereb. Cortex 22, 820–827.
Inan, M., Bla´zquez-Llorca, L., Mercha´n-Pe´rez, A., Anderson, S.A., DeFelipe,
J., and Yuste, R. (2013). Dense and overlapping innervation of pyramidal
neurons by chandelier cells. J. Neurosci. 33, 1907–1914.
Inda, M.C., DeFelipe, J., and Mun˜oz, A. (2009). Morphology and distribution of
chandelier cell axon terminals in the mouse cerebral cortex and claustroamyg-
daloid complex. Cereb. Cortex 19, 41–54.
Laurin, M., Fradet, N., Blangy, A., Hall, A., Vuori, K., and Coˆte´, J.F. (2008). The
atypical Rac activator Dock180 (Dock1) regulates myoblast fusion in vivo.
Proc. Natl. Acad. Sci. USA 105, 15446–15451.
Lewis, D.A. (2012). Cortical circuit dysfunction and cognitive deficits in schizo-
phrenia—implications for preemptive interventions. Eur. J. Neurosci. 35,
1871–1878.
Li, B., Woo, R.S., Mei, L., and Malinow, R. (2007). The neuregulin-1 receptor
erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 54,
583–597.
Marı´n, O. (2012). Interneuron dysfunction in psychiatric disorders. Nat. Rev.
Neurosci. 13, 107–120.
McDonald, A.J. (1982). Neurons of the lateral and basolateral amygdaloid
nuclei: a Golgi study in the rat. J. Comp. Neurol. 212, 293–312.
Meller, N., Merlot, S., and Guda, C. (2005). CZH proteins: a new family of Rho-
GEFs. J. Cell Sci. 118, 4937–4946.
Miyamoto, Y., and Yamauchi, J. (2010). Cellular signaling of Dock family
proteins in neural function. Cell. Signal. 22, 175–182.
Nagy, P., Claus, J., Jovin, T.M., and Arndt-Jovin, D.J. (2010). Distribution of
resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living
cells using number and brightness analysis. Proc. Natl. Acad. Sci. USA 107,
16524–16529.
Ogawa, Y., and Rasband, M.N. (2008). The functional organization and assem-
bly of the axon initial segment. Curr. Opin. Neurobiol. 18, 307–313.
Pierri, J.N., Chaudry, A.S., Woo, T.U., and Lewis, D.A. (1999). Alterations in
chandelier neuron axon terminals in the prefrontal cortex of schizophrenic
subjects. Am. J. Psychiatry 156, 1709–1719.
Prickett, T.D., Agrawal, N.S., Wei, X., Yates, K.E., Lin, J.C., Wunderlich, J.R.,
Cronin, J.C., Cruz, P., Rosenberg, S.A., and Samuels, Y. (2009). Analysis of
the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat.
Genet. 41, 1127–1132.
Randall, K.L., Chan, S.S., Ma, C.S., Fung, I., Mei, Y., Yabas, M., Tan, A.,
Arkwright, P.D., Al Suwairi, W., Lugo Reyes, S.O., et al. (2011). DOCK8 defi-Cciency impairs CD8 T cell survival and function in humans and mice. J. Exp.
Med. 208, 2305–2320.
Sik, A., Tamamaki, N., and Freund, T.F. (1993). Complete axon arborization of
a single CA3 pyramidal cell in the rat hippocampus, and its relationship with
postsynaptic parvalbumin-containing interneurons. Eur. J. Neurosci. 5,
1719–1728.
Somogyi, P. (1977). A specific ‘axo-axonal’ interneuron in the visual cortex of
the rat. Brain Res. 136, 345–350.
Somogyi, P., Freund, T.F., and Cowey, A. (1982). The axo-axonic interneuron
in the cerebral cortex of the rat, cat and monkey. Neuroscience 7, 2577–2607.
Szabadics, J., Varga, C., Molna´r, G., Ola´h, S., Barzo´, P., and Tama´s, G. (2006).
Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits.
Science 311, 233–235.
Taniguchi, H., Lu, J., and Huang, Z.J. (2013). The spatial and temporal origin of
chandelier cells in mouse neocortex. Science 339, 70–74.
Vives, V., Laurin, M., Cres, G., Larrousse, P., Morichaud, Z., Noel, D., Coˆte´,
J.F., and Blangy, A. (2011). The Rac1 exchange factor Dock5 is essential for
bone resorption by osteoclasts. J. Bone Miner. Res. 26, 1099–1110.
Watabe-Uchida, M., John, K.A., Janas, J.A., Newey, S.E., and Van Aelst, L.
(2006). The Rac activator DOCK7 regulates neuronal polarity through local
phosphorylation of stathmin/Op18. Neuron 51, 727–739.
Woo, T.U., Whitehead, R.E., Melchitzky, D.S., and Lewis, D.A. (1998). A
subclass of prefrontal gamma-aminobutyric acid axon terminals are selec-
tively altered in schizophrenia. Proc. Natl. Acad. Sci. USA 95, 5341–5346.
Woodruff, A.R., Anderson, S.A., and Yuste, R. (2010). The enigmatic function
of chandelier cells. Front. Neurosci. 4, 201.
Woodruff, A.R., McGarry, L.M., Vogels, T.P., Inan, M., Anderson, S.A., and
Yuste, R. (2011). State-dependent function of neocortical chandelier cells.
J. Neurosci. 31, 17872–17886.
Yamanashi, Y., Tezuka, T., and Yokoyama, K. (2012). Activation of receptor
protein-tyrosine kinases from the cytoplasmic compartment. J. Biochem.
151, 353–359.
Yamauchi, J., Miyamoto, Y., Chan, J.R., and Tanoue, A. (2008). ErbB2 directly
activates the exchange factor Dock7 to promote Schwann cell migration.
J. Cell Biol. 181, 351–365.
Yang, Y.T., Wang, C.L., and Van Aelst, L. (2012). DOCK7 interacts with TACC3
to regulate interkinetic nuclear migration and cortical neurogenesis. Nat.
Neurosci. 15, 1201–1210.ell Reports 6, 254–263, January 30, 2014 ª2014 The Authors 263
